{
    "nctId": "NCT00012025",
    "briefTitle": "ICI 182780 in Treating Women With Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial Of Fulvestrant (Faslodex) In Women With Metastatic Breast Cancer And Failure on Aromatase Inhibitor Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "objective response rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast\n\n  * Progressive local-regional or metastatic disease\n  * Unconfirmed new or progressive multiple pulmonary nodules or unequivocal radiographic evidence of multiple bone metastases allowed\n* At least 1 measurable lesion\n\n  * At least 20 mm by CT scan or MRI OR at least 10 mm by spiral CT scan\n  * Nonmeasurable disease includes the following:\n\n    * Bone lesions\n    * Leptomeningeal disease\n    * Ascites\n    * Pleural/pericardial effusions\n    * Lymphangitis cutis/pulmonis\n    * Inflammatory breast disease\n    * Abdominal masses not confirmed and followed by imaging techniques\n    * Cystic lesions\n* Disease progression after prior third-generation aromatase inhibitor (e.g., anastrozole, exemestane, letrozole, or vorozole)\n\n  * Failed no more than 1 prior additive hormonal therapy (e.g., aromatase inhibitor with or without tamoxifen)\n\n    * Disease recurrence identified no more than 12 months since the last prior adjuvant tamoxifen treatment\n    * Oophorectomy, ovarian radiotherapy, and luteinizing hormone-releasing hormone (LH-RH) analogs not considered hormonal therapy regimens\n* No brain or leptomeningeal metastases\n* No hepatic metastases involving more than one-third of the liver\n* No symptomatic pulmonary lymphangitic disease\n* Evidence of hormone sensitivity as defined by:\n\n  * Relapse after at least 12 months of adjuvant hormonal treatment\n  * Tumor remission or stabilization before progression for at least 6 months after prior hormonal therapy for advanced disease\n* Postmenopausal as defined by one of the following:\n\n  * At least 12 months since last menstrual period\n  * 4-11 months since last menstrual period and follicle-stimulating hormone (FSH) in the postmenopausal range\n  * Prior castration and castrate FSH levels within the postmenopausal range\n  * Hysterectomy without oophorectomy (FSH in postmenopausal range if age 60 and under)\n* Hormone receptor status:\n\n  * Estrogen-receptor and/or progesterone-receptor positive\n\n    * At least 10 fmol/mg cytosol protein OR\n    * Positive by immunohistochemistry\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* See Disease Characteristics\n* Postmenopausal\n\nPerformance status:\n\n* ECOG 0-2\n\nLife expectancy:\n\n* At least 3 months\n\nHematopoietic:\n\n* WBC at least 2,000/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* No history of bleeding diathesis\n\nHepatic:\n\n* See Disease Characteristics\n* Bilirubin no greater than 0.8 mg/dL above upper limit of normal (ULN)\n* INR no greater than 1.6\n* No hepatitis B or C\n* No severe hepatic impairment\n\nRenal:\n\n* Calcium no greater than 10% above ULN\n* Creatinine no greater than 1 mg/dL above ULN\n* No severe renal impairment\n\nCardiovascular:\n\n* No unstable or uncompensated cardiac condition\n\nPulmonary:\n\n* No unstable or uncompensated respiratory condition\n\nOther:\n\n* HIV negative\n* No AIDS\n* No other severe condition or systemic disease that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Prior trastuzumab (Herceptin) allowed\n\nChemotherapy:\n\n* Prior adjuvant chemotherapy allowed\n* No more than 1 prior chemotherapy regimen for metastatic disease\n\nEndocrine therapy:\n\n* See Disease Characteristics\n* More than 4 weeks since prior estrogen replacement therapy\n* More than 3 months since prior LH-RH analogs\n* No other prior additive hormonal therapy except third-generation aromatase inhibitors or tamoxifen\n\nRadiotherapy:\n\n* See Disease Characteristics\n* Concurrent radiotherapy for control of bone pain or other reasons due to established bone lesions allowed if radiotherapy field is no more than 30% of bone marrow\n\nSurgery:\n\n* See Disease Characteristics\n\nOther:\n\n* More than 4 weeks since prior investigational drug for breast cancer\n* No concurrent long-term warfarin\n* Concurrent bisphosphonates allowed if dose stable\n* Concurrent long-term antiplatelet therapy allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}